Please ensure Javascript is enabled for purposes of website accessibility

Why iBio Stock Is Soaring Today

By Prosper Junior Bakiny – Sep 9, 2020 at 11:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is advancing its most-promising vaccine candidate for the novel coronavirus.

What happened?

Shares of iBio (IBIO 3.16%) were up by 6.8% as of 11:38 a.m. EDT after climbing by as much as 19.5% earlier today, following the company's announcement that it has selected its leading COVID-19 vaccine candidate.

So what

iBio had been working on two experimental vaccines, IBIO-200 and IBIO-201. Both performed well in pre-clinical studies, producing antibodies for the SARS-CoV-2 virus that causes COVID-19. Antibodies are proteins that defend healthy cells from pathogens.

But the biotech found that IBIO-201 "induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice." That is why the company chose IBIO-201 as its leading candidate. The company plans on advancing it to toxicology studies before it reaches the clinical-trial stage. But iBio isn't giving up on IBIO-200; it will continue pre-clinical development for this experimental vaccine.

Doctor holding a glass vial labeled "COVID-19 vaccine coronavirus."

Image source: Getty Images.

Now what 

The race to develop a vaccine for the coronavirus is crowded, with several companies already conducting late-stage studies for their candidates. These include Moderna, AstraZeneca, and Pfizer. With that said, there is a worldwide need for a vaccine, and iBio could still end up launching its vaccine on the market in time to generate healthy revenue. It is also worth noting that iBio has a market cap of just $362.78 million as of this writing.

The company's shares will tend to be more susceptible to upward movements than others with much larger market caps when it announces the progress of its COVID-19 program. But if it fails to impress investors, its stock will crash. iBio rose by as much as 2,470% earlier this year, and it's now up by a more modest (but still impressive) 739.4% year to date. In other words, this biotech stock will remain volatile, and only investors who can stomach the risk should consider initiating a small position in iBio. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iBio Stock Quote
iBio
IBIO
$1.63 (3.16%) $0.05
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.17 (0.08%) $0.05
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.